Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 719,000 Ordinary Shares on September 2, 2013.
- Price Range: Highest price paid was 1,677.50 pence; lowest price paid was 1,651.00 pence.
- Treasury Holdings (Settled): 514,835,412 shares (9.51% of total issued share capital).
- Treasury Holdings (Including Unsettled): 517,760,412 shares (10.57% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,898,774,071 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 719,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.57% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (4,898,774,071) for calculating disclosure thresholds under FCA rules.
- Confirm the current percentage of voting rights held in Treasury (10.57% including unsettled shares).
- Review the price paid per share (1,651.00 to 1,677.50 pence) against market prices on September 2, 2013.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial metrics.